Effect of High-Dose Oral Rabeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcers

Table 4

Number (%) of patients who discontinued the study grouped by primary reason (ITT population).

	Oral rabeprazole group (𝑛=54)	IV omeprazole group (𝑛=52)
Loss to followup at 6 weeks	21 (38.9%)	14 (26.9%)
Detection of exclusion criteria after enrollment*	4 (7.4%)	3 (5.8%)
Patient request	0	1 (1.9%)
Protocol violation	0	1 (1.9%)
Total	25 (46.3%)	19 (36.5%)

ITT: intention-to-treat; IV: intravenous.
*Detection of exclusion criteria after enrollment included lung cancer, stomach cancer at another site, bleeding of a gastric adenoma, Billroth II subtotal gastrectomy, and bleeding of a duodenal submucosal tumor.